Bryan Lewis

May 05, 2022

Bryan Lewis, president of KidneyCAN, and Chung-Han Lee, MD, describe unmet needs and future perspectives in the treatment of renal cell carcinoma.

May 05, 2022

Meryl Uranga describes her path with metastatic clear cell renal cell carcinoma after first treatment, and how it has affected her outlook on her life and future.

May 05, 2022

A look at how to consider quality-of-life clinical trial and patient-reported data when treating clear cell renal cell carcinoma with combination therapies.

May 02, 2022

Meryl Uranga describes her personal experience with managing the side effects of treatment for clear cell renal cell carcinoma.

May 02, 2022

An overview of side effects commonly seen with lenvatinib plus pembrolizumab for the treatment of clear cell renal cell carcinoma.

April 21, 2022

Clinical nurse Kiran Virdee explains why a multidisciplinary treatment approach to clear cell renal cell carcinoma is beneficial.

April 21, 2022

An oncologist describes the necessity of discussing options with a patient when picking a treatment approach for clear cell renal cell carcinoma.

April 19, 2022

A review of clinical trial data on combination treatments for clear cell renal cell carcinoma.

April 19, 2022

Patients with clear cell renal cell carcinoma speak to their experiences with systemic treatments.

April 08, 2022

An overview of first-line treatment options for metastatic clear cell renal cell carcinoma.

April 08, 2022

Bryan Lewis, president of KidneyCAN, explains how his organization supports the renal cell carcinoma community and where patients can find curated educational resources.

March 30, 2022

Patient Meryl Uranga describes how she was diagnosed with metastatic clear cell renal cell carcinoma and the initial treatments she received.

March 30, 2022

Chung-Han Lee, M.D., provides background on clear cell renal cell carcinoma, including common symptoms and risk factors.